Hemophilia A – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology's coverage of hemophilia A comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of hemophilia A for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's hemophilia A forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of dyslipidemai?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of hemophilia A?
- Of all people diagnosed with hemophilia A, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hemophilia A over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Note: Coverage may vary by country.
Table of contents
- Hemophilia A - Epidemiology - Epidemiology Dashboard
- Introduction
- Epidemiology Dashboard
- Introduction
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.